轉基因生物（GMO）小組此前就轉基因大豆BPS - CV127 - 9預期用途對人類和動物健康及環(huán)境的潛在影響做了風險評估，發(fā)現(xiàn)這種大豆與傳統(tǒng)大豆和商業(yè)大豆品種一樣安全和有營養(yǎng)。2018年2月16日，應歐盟委員會要求，歐盟食品安全局分析轉基因大豆BPS - CV127 - 9的新核酸測序數(shù)據(jù)和更新的生物信息學數(shù)據(jù)，并指出轉基因大豆BPS - CV127 - 9安全小組先前的結論是否仍然有效。經(jīng)過評估，新的測序數(shù)據(jù)和對新序列進行的生物信息學分析沒有引起安全問題。因此，EFSA得出結論，大豆BPS - CV127 - 9的原始風險評估仍然有效。

 

    部分原文報道如下：

 

    The GMO Panel has previously assessed genetically modified （GM） soybean BPS‐CV127‐9. This soybean was found to be as safe and nutritious as its conventional counterpart and commercial soybean varieties with respect to potential effects on human and animal health and the environment in the context of its intended uses. On 16 February 2018, European Commission requested EFSA to analyse new nucleic acid sequencing data and updated bioinformatics data for GM soybean BPS‐CV127‐9 and to indicate whether the previous conclusions of the GMO Panel on safety of GM soybean BPS‐CV127‐9 remain valid. The new sequencing data indicated a two nucleotide difference in the unannotated Arabidopsis genomic DNA sequence downstream of the 3′ untranslated region of the ahasl （also referred to as csr1‐2） gene as compared to the sequencing data originally provided. One of these nucleotide differences reported in the new nucleic acid sequencing data from GM soybean event BPS‐CV127‐9 was shown to be already present in the original plant material used for the risk assessment. However, for the other nucleotide difference reported, no evidence could be provided to differentiate between a sequencing error and point‐mutation. With the exception of bioinformatics analyses, the studies performed for the risk assessment of the single event soybean BPS‐CV127‐9 remain valid. The new sequencing data and the bioinformatics analyses performed on the new sequence did not give rise to safety issues. Therefore, EFSA concludes that the original risk assessment of soybean BPS‐CV127‐9 remains valid.

 

    本文由食品伙伴網(wǎng)食品資訊中心編輯，供網(wǎng)友參考，歡迎轉載，轉載請注明出處！有任何疑問，請聯(lián)系news@foodmate.net。